NovoCure Q4 Earnings Call Highlights

Leonard said the company’s glioblastoma (GBM) business remains core. In 2025, NovoCure saw active patient growth across major markets, driven primarily outside the U.S. He cited year-over-year active patient growth of 10% in Germany, 19% in France and 29% in Japan, along with 4% growth in the U.S., which he said had been flat in recent years. For 2026, management expects growth rates to stabilize in the “low to mid-single digit” range as markets mature, with modest first-year contributions expected from lau ...